Serina Therapeutics, Inc.
SER NYSE
SEC CIK 1708599
Follow Serina Therapeutics
Weekly email: filings, results
Revenue, last quarter
$125K
Net income
−$7.9M
−72.4% vs same quarter last year
EPS, diluted
−$0.31
+31.1% vs same quarter last year
Operating cash flow
−$5.5M
−42.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $130K | −$19.2M |
| FY24 | $56K | −$11.1M |
| FY23 | $3.2M | $5.3M |
| FY22 | $34K | −$10.5M |
| FY21 | $144K | −$8.7M |
| FY20 | $361K | −$10.9M |
| FY19 | $1.7M | −$12.2M |
| FY18 | $1.4M | −$7.5M |
| FY17 | $1.4M | −$6.6M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −18478.5% | −14755.4% |
| FY24 | - | −30442.9% | −19894.6% |
| FY23 | 3.2% | −99.2% | 167.1% |
| FY22 | 61.8% | −20514.7% | −30770.6% |
| FY21 | 86.8% | −5509% | −6024.3% |
| FY20 | 92.8% | −2797.8% | −3009.7% |
| FY19 | 85.9% | −726.8% | −703.4% |
| FY18 | 73.9% | −805.5% | −537.4% |
| FY17 | 88% | −474.6% | −468.7% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$18M |
| FY24 | −$17.2M |
| FY23 | −$3M |
| FY22 | - |
| FY21 | - |
| FY20 | −$7.8M |
| FY19 | −$10.8M |
| FY18 | −$8M |
| FY17 | −$6.3M |
| FY16 | - |
- Serina Therapeutics
- Healthcare median
Show the numbers
| Year | Serina Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −14755.4% | −30.6% |
| FY24 | −19894.6% | −47% |
| FY23 | 167.1% | −58% |
| FY22 | −30770.6% | −80.4% |
| FY21 | −6024.3% | −71.9% |
| FY20 | −3009.7% | −62.2% |
| FY19 | −703.4% | −46.3% |
| FY18 | −537.4% | −49.6% |
| FY17 | −468.7% | −45.9% |
| FY16 | - | −36% |